HK Stock Market Move | INNOGEN-B(02591) morning rise by over 43%Suba's Phase III weight loss data expected to be announced by the end of 2026.

INNOGEN-B(02591) rose by more than 43% in the morning, and as of the time of writing, it was up by 42.21%, closing at 17.99 Hong Kong dollars with a trading volume of 173 million Hong Kong dollars. On the news front, Yinnuo Pharma's annual performance showed revenues of 132 million yuan and a loss of 341 million yuan in 2025. It is worth noting that the lock-up period for Yinnuo Pharma's cornerstone investors will expire on May 14, 2026, and the relevant shares will be officially released for trading on May 15. The cornerstone investors collectively hold 4.201 million shares. Sealand released a research report stating that Suba T2D received NMPA certification for its indications in January 2025 and has been included in the national medical insurance catalog. The Phase III weight loss data for Suba is expected to be announced by the end of 2026. The report pointed out that in the Phase IIb study, the 20 mg once-weekly dosing regimen achieved a 10.6% weight reduction at week 18 with no observed plateau, while the 20 mg once every two weeks dosing regimen achieved a 9.7% weight reduction at week 18. The Phase III clinical trial for treating obesity and overweight patients completed patient enrollment in 2025. The top-line data for this trial is expected to be announced by the end of 2026.